NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions, has scheduled its Q2 2025 earnings call for Tuesday, August 12, 2025, at 9:00 AM ET. The financial results will be released before the market opens.
The company will host a live webcast accessible through their investor relations website, with options for participants to submit questions through the webcast portal or via email. A replay of the webcast will be available on the company's website following the call.
NeurAxis (NYSE American: NRXS), un'azienda di tecnologia medica specializzata in terapie di neuromodulazione per condizioni croniche, ha programmato la sua conference call sui risultati del secondo trimestre 2025 per martedì 12 agosto 2025 alle 9:00 AM ET. I risultati finanziari saranno divulgati prima dell'apertura dei mercati.
L'azienda trasmetterà un webcast in diretta accessibile tramite il sito web dedicato agli investitori, offrendo ai partecipanti la possibilità di inviare domande tramite il portale del webcast o via email. Una registrazione del webcast sarà disponibile sul sito dell'azienda dopo la chiamata.
NeurAxis (NYSE American: NRXS), una empresa de tecnología médica centrada en terapias de neuromodulación para condiciones crónicas, ha programado su llamada de resultados del segundo trimestre de 2025 para el martes 12 de agosto de 2025 a las 9:00 AM ET. Los resultados financieros se publicarán antes de la apertura del mercado.
La empresa realizará una transmisión en vivo accesible a través de su sitio web de relaciones con inversionistas, con opciones para que los participantes envíen preguntas a través del portal del webcast o por correo electrónico. Una repetición del webcast estará disponible en el sitio web de la empresa después de la llamada.
NeurAxis (NYSE American: NRXS)는 만성 질환을 위한 신경조절 치료에 중점을 둔 의료 기술 회사로, 2025년 8월 12일 화요일 오전 9시(동부시간)에 2025년 2분기 실적 발표 컨퍼런스 콜을 예정하고 있습니다. 금융 실적은 시장 개장 전에 공개됩니다.
회사는 투자자 관계 웹사이트를 통해 실시간 웹캐스트를 진행하며, 참가자들은 웹캐스트 포털이나 이메일을 통해 질문을 제출할 수 있습니다. 컨퍼런스 콜 후에는 회사 웹사이트에서 웹캐스트 다시보기 서비스를 제공할 예정입니다.
NeurAxis (NYSE American : NRXS), une entreprise de technologie médicale spécialisée dans les thérapies de neuromodulation pour les affections chroniques, a programmé sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le mardi 12 août 2025 à 9h00 ET. Les résultats financiers seront publiés avant l'ouverture des marchés.
L'entreprise diffusera un webcast en direct accessible via son site web dédié aux relations investisseurs, offrant aux participants la possibilité de poser des questions via le portail du webcast ou par e-mail. Un replay du webcast sera disponible sur le site de la société après la conférence téléphonique.
NeurAxis (NYSE American: NRXS), ein Medizintechnologieunternehmen mit Schwerpunkt auf Neuromodulationstherapien für chronische Erkrankungen, hat seine Ergebnispräsentation für das zweite Quartal 2025 am Dienstag, den 12. August 2025, um 9:00 Uhr ET angesetzt. Die Finanzergebnisse werden vor Marktöffnung veröffentlicht.
Das Unternehmen wird ein Live-Webcast über seine Investor-Relations-Website anbieten, bei dem Teilnehmer Fragen über das Webcast-Portal oder per E-Mail einreichen können. Eine Aufzeichnung des Webcasts wird nach dem Anruf auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time
CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Tuesday, August 12, 2024, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/8yd7cjue. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following Call In Link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/8yd7cjue.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis (NRXS) release its Q2 2025 earnings?
How can investors access the NeurAxis Q2 2025 earnings call?
What is NeurAxis's (NRXS) main business focus?
How can investors submit questions during the NeurAxis earnings call?
